Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

This publication has 19 references indexed in Scilit:

• Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease
  JAMA, 1998
• A Randomized Trial of the Effects of Atorvastatin and Niacin in Patients with Combined Hyperlipidemia or Isolated Hypertriglyceridemia
  The American Journal of Medicine, 1998
• Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men
  Circulation, 1997
• Small LDL, Atherogenic Dyslipidemia, and the Metabolic Syndrome
  Circulation, 1997
• Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS)
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1996
• Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients With Hypertriglyceridemia
  JAMA, 1996
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
• Does measurement of apolipoprotein B have a place in cholesterol management?
  Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990
• Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
  Circulation, 1990